Indian Journal of Nephrology Home 

CASE REPORT
[Download PDF]
Year : 2016  |  Volume : 26  |  Issue : 3  |  Page : 212--215

Role of diffusion weighted imaging in diagnosis of post transplant lymphoproliferative disorders: Case reports and review of literature

A Singh1, CJ Das1, AK Gupta1, S Bagchi2,  
1 Department of Radiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
2 Department of Nephrology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India

Correspondence Address:
C J Das
Department of Radiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi - 110 029
India

Abstract

Post transplant lymphoproliferative disorder include a spectrum of conditions occurring in immunosuppressed post transplant recipients, lymphoma being the most ominous. 18F-fludeoxyglucose positron emission tomography with computed tomography CT) is the current imaging gold standard for lymphoma imaging as it allows both morphological and functional assessment. CT and/or conventional magnetic resonance imaging (MRI) are used for morphological evaluation in transplant recipients. Integrating diffusion weighted imaging with apparent diffusion coefficient analysis in MRI protocol enhances its sensitivity and may prove invaluable in response assessment in transplant recipients.

How to cite this article:
Singh A, Das C J, Gupta A K, Bagchi S. Role of diffusion weighted imaging in diagnosis of post transplant lymphoproliferative disorders: Case reports and review of literature.Indian J Nephrol 2016;26:212-215

How to cite this URL:
Singh A, Das C J, Gupta A K, Bagchi S. Role of diffusion weighted imaging in diagnosis of post transplant lymphoproliferative disorders: Case reports and review of literature. Indian J Nephrol [serial online] 2016 [cited 2020 May 25 ];26:212-215
Available from: http://www.indianjnephrol.org/text.asp?2016/26/3/212/163430

Full Text



 Introduction



Post transplant lymphoproliferative disorders (PTLD) include myriad of lymphoproliferative manifestations occurring in transplant recipients ranging from innocuous flu like conditions (mononucleosis) to the development of aggressive widely disseminated malignancy (lymphoma).[1] PTLD is a rare, but potentially fatal complication seen in ~1% of transplant recipients (solid and stem cell).[1],[2]

Risk factors for developing PTLD are multifactorial which includes Epstein–Barr virus (EBV) seronegativity, immunosuppression administered to recipients (intensity, amount, and duration), co-existing cytomegalo virus or hepatitis C infection, cadaveric donor and use of anti CD3 monoclonal antibody. The incidence of PTLD is higher in pediatric patients who are usually EBV seronegative.[1],[3]. The overall incidence of PTLD is least in renal transplant (nearly 13%) as compared to other solid organ transplant recipients (~15%).[4] PTLD most frequently involves extra nodal sites with reportedly highest incidence in gastro-intestinal tract and allograft. However, it can involve any organ including skin and brain.[1],[5] Clinically, PTLD is a great masquerader, the diagnosis of which rests on a high index of clinical suspicion. It can manifests with a variety of nonspecific symptoms that may resemble any other post transplant complications including graft rejection and sepsis.[1],[6]

Compared to lymphoma occurring in general population, PTLD lymphoma carries a dismal prognosis (nearly 30–60% mortality)[1],[5],[7] with an aggressive downhill course; hence, timely diagnosis is warranted. As majority of these cases are diagnosed on imaging, radiologists should be familiar with its morphological gamut. Further, timely diagnosis will expedite the management which in most cases consists of mere reduction of the degree of immunosuppresant only.

 Case Reports



Case 1

A 36 years old male presented in emergency with complaints of fever, weight loss, and vague upper abdominal pain of 1-month duration. Renal allograft transplantation had been done 1-year back and he was kept on immunosuppresants (azathioprine, cyclosporine and prednisolone). Ultrasonography (USG) abdomen revealed multiple conglomerate as well discrete hypoechoic solid lesions in upper abdomen in mesentery and peripancreatic locations. Contrast enhanced computed tomography (CECT) abdomen showed multiple non-necrotic, non calcified lesions in central mesentery and upper retroperitoneum [Figure 1]a. Bowel and vascular encasement were present with no obstruction or luminal compromise. On magnetic resonance imaging (MRI), lesions were mildly hyperintense on T2-weighted image, however, marked diffusion restriction was present with corresponding hypointensity on apparent diffusion coefficient (ADC) images [Figure 1]b,[Figure 1]c,[Figure 1]d,[Figure 1]e. Provisional diagnosis of PTLD related lymphoma was kept. USG guided biopsy revealed diffuse large B-cell lymphoma. Subsequently immunosuppressants doses were lowered and chemotherapy started. Follow-up MRI 2 months later revealed complete resolution of lesions.{Figure 1}

Case 2

A 40 years old male renal transplant recipient came to emergency with vomiting and jaundice, 2 years post transplant, maintained on immunosuppression (cyclosporine and prednisolone). USG showed mild bilobar intrahepatic biliary dilatation and dilated common bile duct (CBD). CECT abdomen revealed circumferential nodular hypodense mural thickening involving second part of duodenum causing mild upstream dilatation of CBD and intrahepatic biliary radicles [Figure 2]a. MRI done 2 weeks later showed similar findings with mildly T2 hypointense mural thickening involving second part of duodenum showing markedly restricted diffusion and hypointensity on ADC images [Figure 2]b,[Figure 2]c,[Figure 2]d,[Figure 2]e. Degree of proximal CBD dilatation and intrahepatic biliary dilatation had increased. Upper gastrointestinal (GI) endoscopy and biopsy revealed diffuse large B-cell lymphoma. Immunnosuppressants were stopped and patient was put on chemotherapy. However, the patient succumbed to his illness 15 days after initiation of chemotherapy due to fungal pneumonia.{Figure 2}

 Discussion



PTLD of abdomen can present with nonspecific symptoms like pyrexia of unknown origin, weight loss, irritability, lymphadenopathy, or more specific symptoms which may vary from indolent pharyngitis and diarrhea to acute abdomen due to obstruction, GI bleed or perforation due to its higher tendency for ulceration as compared to lymphoma occurring in immunocompetent individuals.[8],[9],[10]

PTLD related lymphoma most commonly involves gastrointestinal tract (GIT), followed by the central nervous system and kidneys.[10] Distal small intestine is the most common hollow viscera to be involved, followed by proximal colon, stomach, duodenum, and esophagus. For GIT associated PTLD, pan endoscopy remains useful tool for the initial diagnosis, management, and treatment.[3] CECT is the most widespread imaging modality in diagnosing lymphoma due to its relative low cost and easy availability. Diagnosis of PTLD on CECT rests on morphological evaluation with the lesions being solid and either hypo or nonenhancing. Failure to provide functional information coupled with inability to distinguish residual disease from fibrosis remains its lacunae.[2],[10],[11],[12]18 F-fludeoxyglucose positron emission tomography with computed tomography (18 F-FDG PET/CT) is currently the imaging gold standard for lymphoma evaluation with lesions being FDG avid. It provides the dual advantage of providing both morphological and functional information, thus proving invaluable in diagnosing, staging, and response assessment. Sensitivity and specificity of PET/CT in initial staging approaches 100% regardless of lymphoma grade. Moreover, quantifying standardized uptake value helps in assessing metabolic activity in tumor and may help in vitro diagnosing the aggressiveness of lymphoma. However, high radiation exposure and costs remain its limitations.[11],[12],[13],[14],[15]

Conventional MRI sequences, much like CT helps in morphological assessment only. However, due to its superior spatial resolution and radiation free modality, it scores over CT, hence benefitting in evaluating extra-nodal disease. Due to compromised renal function in postrenal transplant recipients, iodinated nonionic contrast usage is discouraged; hence MRI is preferred over CECT for morphological assessment if available.[13]

Lymphoma is hypointense on T1-weighted, mildly hyperintense on T2 weighted sequences and shows minimal enhancement if any on postcontrast images. Diffusion weighted imaging (DWI) is increasingly being used in lymphoma evaluation on which it shows restricted diffusion due to hypercellularity.[11] Calculation of ADC value provide quantitative information which adds to the functional assessment of disease, thus, helping in staging, grading, and response assessment following treatment.[11]

By adding whole body diffusion weighted imaging with background suppression (DWIBS) in lymphoma assessment protocol, MRI is comparable to FDG-PET/CT as it also provides one stop shop for diagnosis, staging and therapeutic response assessment. Furthermore, inverted gray scale DWIBS images are alike PET images with added advantage of increased lesion conspicuity and no radiation exposure.[10],[11]

To the best of our knowledge, no study in literature until date has described the incremental utility of DWI in management of PTLD. Due to increased accuracy in lymphoma detection we recommend incorporation of DWI in while performing MRI in PTLD which not only guide tissue sampling of these lesions but can also be very useful to evaluate treatment response in terms of ADC calculation.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int 2007;20:207-18.
2Vrachliotis TG, Vaswani KK, Davies EA, Elkahammas EA, Bennett WF, Bova JG. CT findings in posttransplantation lymphoproliferative disorder of renal transplants. AJR Am J Roentgenol 2000;175:183-8.
3Cader RA, Mohd R, Gafor HA, Kong NC. Post transplant lymphoproliferative disorder: A case series and review of literature. EXCLI J 2013;12:144-9.
4Chia SC, Chau YP, Tan YM. Late-onset post-transplant lymphoproliferative disease presenting as massive occult gastrointestinal haemorrhage. Singapore Med J 2008;49:e117-20.
5O'Connor JA, Cogley C, Burton M, Lancaster-Weiss K, Cordle RA. Posttransplantation lymphoproliferative disorder: Endoscopic findings. J Pediatr Gastroenterol Nutr 2000;31:458-61.
6Badham K, Mirchandani A, Arumainayagam N, West DR. Epstein-Barr virus associated with a post-transplant lymphoproliferative disorder presenting as isolated gastrointestinal tract bleeding. Endoscopy 2007;39 Suppl 1:E64-5.
7Caillard S, Lelong C, Pessione F, Moulin B, French PTLD Working Group. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French Registry. Am J Transplant 2006;6:2735-42.
8Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: A review. Bone Marrow Transplant 2003;31:145-55.
9Mishra S, Khan NH, Bonsal R, Kher V, Ahlawat R, Yadav RV. Lymphoproliferative disorder following renal transplantation. Indian J Transplant 2005;1:33-6.
10Camacho JC, Moreno CC, Harri PA, Aguirre DA, Torres WE, Mittal PK. Posttransplantation lymphoproliferative disease: Proposed imaging classification. Radiographics 2014;34:2025-38.
11Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL. Whole-body diffusion-weighted imaging: The added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 2011;197:W384-91.
12Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-8.
13Ali MG, Coakley FV, Hricak H, Bretan PN. Complex posttransplantation abnormalities of renal allografts: Evaluation with MR imaging. Radiology 1999;211:95-100.
14Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005;23:4643-51.
15La Fougère C, Hundt W, Bröckel N, Pfluger T, Haug A, Scher B, et al. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2006;33:1417-25.